A new deal on a sustained release cannabinoid product is a positive, but Emblem Corp’s (TSXV:EMC) pharmaceutical strategy faces a “lengthy and … Read More
The post Emblem Corp’s pharma strategy faces long road, Canaccord Genuity says appeared first on Dagga Magazine.